drugset / Trial / NCT05596526
Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to provide evidence as to whether RZV is immunogenic with an acceptable safety profile in Multiple Sclerosis patients on anti-CD20 treatment.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2024-12-31
- Completion
- 2025-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | VARICELLA ZOSTER VIRUS ENVELOPE GLYCOPROTEIN E | Vaccine | — | — |